IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.
Patients are very satisfied with Mohs micrographic surgery (MMS) for melanoma in situ, according to a research letter recently published in Dermatologic Surgery.